Clinical Trial Update: Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update describing the use of immunoglobulin therapy in multiple myeloma patients treated with a BCMA-directed T cell engager; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA-directed T cell engager (BCMA-directed T cell engager)
• Intravenous Immunoglobulin (IVIG)

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: Multiple Myeloma Refractory, Relapsed Multiple Myeloma | Phase 4 | Status: RECRUITING